Pertuzumab: differenze tra le versioni
Vai alla navigazione
Vai alla ricerca
Contenuto cancellato Contenuto aggiunto
Wikipedia:Bot/Richieste/Errori comuni, refusi, ecc., replaced: è è → è using AWB |
ins. bibl. |
||
| Riga 41: | Riga 41: | ||
== Note== |
== Note== |
||
<references/> |
<references/> |
||
== Bibliografia == |
|||
* {{cite book|author=Frank Ashall|title=Le grandi scoperte scientifiche|url=http://books.google.com/books?id=GXsecqAh6MEC&pg=PA245|accessdate=|year=1999|publisher=Armando Editore|isbn=9788871449494|pages=245–}} |
|||
* {{cite book|author1=Abul K. Abbas|author2=Andrew H. Lichtman|author3=Shiv Pillai|title=Immunologia cellulare e molecolare|url=http://books.google.com/books?id=9SFm3nMO_gUC&pg=PA79|accessdate= |year=2010|publisher=Elsevier srl|isbn=9788821431760|pages=79–}} |
|||
* {{cite book|author1=Abul K. Abbas|author2=Andrew H. Lichtman|title=Le basi dell'immunologia|url=http://books.google.com/books?id=szHkdI9buskC&pg=PA70|accessdate|year=2006|publisher=Elsevier srl|isbn=9788885675858|pages=70–}} |
|||
* {{cite book|author1=Humphrey P. Rang|author2=M. Maureen Dale|author3=James M. Ritter|title=Farmacologia|url=http://books.google.com/books?id=HGcP_ip4SmgC&pg=PA778|accessdate|year=2008|publisher=Elsevier srl|isbn=9788821430237|pages=778–}} |
|||
* {{cite book|author=Enzo Fagiolo|title=Immunoematologia|url=http://books.google.com/books?id=ErRtMU7SKhkC&pg=PA16|accessdate=|year=2007|publisher=Mediserve s.r.l.|isbn=9788882041359|pages=16–}} |
|||
* {{cite book|author=Paolo Larizza|title=Trattato di medicina interna|url=http://books.google.com/books?id=Rt4_C55_Ls4C&pg=PA909|accessdate=|year=2005|publisher=PICCIN|isbn=9788829917211|pages=909–}} |
|||
* {{cite book|author=Angelo Sghirlanzoni|title=Terapia Delle Malattie Neurologiche|url=http://books.google.com/books?id=LCNUGXlL4FQC&pg=PA113|accessdate= |date=3 April 2010|publisher=Springer|isbn=9788847011199|pages=113–}} |
|||
* {{cite book|author=Thomas C. King|title=Patologia|url=http://books.google.com/books?id=1CgV-Td_I3oC&pg=PA156|accessdate= |year=2008|publisher=Elsevier srl|isbn=9788821430190|pages=156–}} |
|||
* {{cite web | url = http://whqlibdoc.who.int/druginfo/INN_2000_list43.pdf WHO-Lista INN degli Anticorpi monoclonali| title = whqlibdoc.who.int | author = | authorlink = | coauthors = | date =|format = | work = | publisher = | pages = | language = en | archiveurl = | archivedate = | quote =| accessdate = }} |
|||
* {{en}}{{cite book|author=Marie A. Simmons|title=Monoclonal antibodies: new research|url=http://books.google.com/books?id=jxhKskARw6IC|accessdate=|year=2005|publisher=Nova Publishers|isbn=9781594542473}} |
|||
* {{en}}{{cite book|author=Zhiqiang An|title=Therapeutic Monoclonal Antibodies: From Bench to Clinic|url=http://books.google.com/books?id=agdx2rtK7E0C|accessdate= |date=8 September 2009|publisher=John Wiley and Sons|isbn=9780470117910}} |
|||
* {{en}}{{cite book|author=James W. Goding|title=Monoclonal antibodies: principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry and immunology|url=http://books.google.com/books?id=jPk4ZY4CnQQC|accessdate=|year=1996|publisher=Academic Press|isbn=9780122870231}} |
|||
* {{en}}{{cite book|author=Steve Shire|title=Current Trends in Monoclonal Antibody Development and Manufacturing|url=http://books.google.com/books?id=YTbJpdPhgT4C|accessdate= |date=April 2009|publisher=Springer|isbn=9780387766423}} |
|||
=== Pertuzumab === |
|||
* {{en}}{{cite book|author=Christoph C. Zielinski|title=Drugs for HER2-positive Breast Cancer|url=http://books.google.com/books?id=rc-PD4F4k6MC&pg=PA81|accessdate=27 March 2011|date=30 November 2010|publisher=Springer|isbn=9783034600934|pages=81–}} |
|||
* {{en}}{{cite book|author1=Gail M. Wilkes|author2=Gail M Wilkes|author3=R.N.|coauthors=M.S., Margaret Barton-Burke, Margaret Barton-Burke, R.N., PH.D.|title=Oncology Nursing Drug Handbook 2011|url=http://books.google.com/books?id=AQVTdGEjrv8C&pg=PA503|accessdate= |date=14 December 2010|publisher=Jones & Bartlett Publishers|isbn=9781449600136|pages=503–}} |
|||
* {{en}}{{cite book|author1=Bruce A. Chabner|author2=Dan L. Longo|title=Cancer Chemotherapy and Biotherapy: Principles and Practice|url=http://books.google.com/books?id=WL4arNFsQa8C&pg=PA521|accessdate= |date=8 November 2010|publisher=Lippincott Williams & Wilkins|isbn=9781605474311|pages=521–}} |
|||
* {{en}}{{cite book|author=Howard L. Kaufman|title=Molecular targeting in oncology|url=http://books.google.com/books?id=btrKJcK6Kn4C&pg=PA390|accessdate= |year=2008|publisher=Humana Press|isbn=9781588295774|pages=390–} |
|||
{{Portale|medicina}} |
{{Portale|medicina}} |
||
Versione delle 14:09, 27 mar 2011
Template:Disclaimer medico Template:Farmaco
Il pertuzumab chiamato anche 2C4, nome commerciale Omnitarg, è un anticorpo monoclonale ricombinante umanizzato. Primo di una classe di agenti chiamati inibitori della dimerizzazione HER. Legandosi HER2, inibisce la dimerizzazione di questo HER2 con altri recettori HER, ciò si ipotizza possa portare ad un rallentamento della crescita tumorale.[1]
Il pertuzumab è sviluppato dalla Genentech. Le prime sperimentazioni cliniche di pertuzumab sono state fatte nel carcinoma della prostata, della mammella e nel Carcinoma dell'ovaio; esse hanno determinato un modesto risultato clinico.[2]
Note
- ^ Johann S. de Bono, Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer, in Journal of Clinical Oncology, vol. 25, n. 3, 20 January 2007, pp. 257–262, DOI:10.1200/JCO.2006.07.0888.
- ^ Genentech press release - May 15, 2005
Bibliografia
- Frank Ashall, Le grandi scoperte scientifiche, Armando Editore, 1999, pp. 245–, ISBN 9788871449494.
- Immunologia cellulare e molecolare, Elsevier srl, 2010, pp. 79–, ISBN 9788821431760.
- Le basi dell'immunologia, Elsevier srl, 2006, pp. 70–, ISBN 9788885675858.
- Farmacologia, Elsevier srl, 2008, pp. 778–, ISBN 9788821430237.
- Enzo Fagiolo, Immunoematologia, Mediserve s.r.l., 2007, pp. 16–, ISBN 9788882041359.
- Paolo Larizza, Trattato di medicina interna, PICCIN, 2005, pp. 909–, ISBN 9788829917211.
- Angelo Sghirlanzoni, Terapia Delle Malattie Neurologiche, Springer, 3 April 2010, pp. 113–, ISBN 9788847011199.
- Thomas C. King, Patologia, Elsevier srl, 2008, pp. 156–, ISBN 9788821430190.
- (EN) WHO-Lista INN degli Anticorpi monoclonali whqlibdoc.who.int.
- (EN) Marie A. Simmons, Monoclonal antibodies: new research, Nova Publishers, 2005, ISBN 9781594542473.
- (EN) Zhiqiang An, Therapeutic Monoclonal Antibodies: From Bench to Clinic, John Wiley and Sons, 8 September 2009, ISBN 9780470117910.
- (EN) James W. Goding, Monoclonal antibodies: principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry and immunology, Academic Press, 1996, ISBN 9780122870231.
- (EN) Steve Shire, Current Trends in Monoclonal Antibody Development and Manufacturing, Springer, April 2009, ISBN 9780387766423.
Pertuzumab
- (EN) Christoph C. Zielinski, Drugs for HER2-positive Breast Cancer, Springer, 30 November 2010, pp. 81–, ISBN 9783034600934. URL consultato il 27 March 2011.
- (EN) M.S., Margaret Barton-Burke, Margaret Barton-Burke, R.N., PH.D., Oncology Nursing Drug Handbook 2011, Jones & Bartlett Publishers, 14 December 2010, pp. 503–, ISBN 9781449600136.
- (EN) Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott Williams & Wilkins, 8 November 2010, pp. 521–, ISBN 9781605474311.
- (EN) {{cite book|author=Howard L. Kaufman|title=Molecular targeting in oncology|url=http://books.google.com/books?id=btrKJcK6Kn4C&pg=PA390%7Caccessdate= |year=2008|publisher=Humana Press|isbn=9781588295774|pages=390–}